It has been reported that RAFi resistant tumor cells acquire resistance due to increased CRAF activity via a transition from BRAF to CRAF-dominated bypass signaling, and the use of CRAFi in combination or pan-RAFi has been used to improve therapeutic efficacy. This evidence concerns the gene BRAF and neoplasm.